Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

Br J Pharmacol. 2002 Jan;135(2):333-43. doi: 10.1038/sj.bjp.0704484.

Abstract

BAY 41-8543 is a novel, highly specific and so far the most potent NO-independent stimulator of sGC. Here we report the effects of BAY 41-8543 on the isolated enzyme, endothelial cells, platelets, isolated vessels and Langendorff heart preparation. BAY 41-8543 stimulates the recombinant sGC concentration-dependently from 0.0001 microM to 100 microM up to 92-fold. In combination, BAY 41-8543 and NO have synergistic effects over a wide range of concentrations. Similar results are shown in implying that BAY 41-8543 stimulates the sGC directly and furthermore makes the enzyme more sensitive to its endogenous activator NO. In vitro, BAY 41-8543 is a potent relaxing agent of aortas, saphenous arteries, coronary arteries and veins with IC(50)-values in the nM range. In the rat heart Langendorff preparation, BAY 41-8543 potently reduces coronary perfusion pressure from 10(-9) to 10(-6) g ml(-1) without any effect on left ventricular pressure and heart rate. BAY 41-8543 is effective even under nitrate tolerance conditions proved by the same vasorelaxing effect on aortic rings taken either from normal or nitrate-tolerant rats. BAY 41-8543 is a potent inhibitor of collagen-mediated aggregation in washed human platelets (IC(50)=0.09 microM). In plasma, BAY 41-8543 inhibits collagen-mediated aggregation better than ADP-induced aggregation, but has no effect on the thrombin pathway. BAY 41-8543 is also a potent direct stimulator of the cyclic GMP/PKG/VASP pathway in platelets and synergizes with NO over a wide range of concentrations. These results suggest that BAY 41-8543 is on the one hand an invaluable tool for studying sGC signaling in vitro and on the other hand its unique profile may offer a novel approach for treating cardiovascular diseases.

MeSH terms

  • Animals
  • Aorta / drug effects
  • Aorta / enzymology
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology
  • Dogs
  • Dose-Response Relationship, Drug
  • Enzyme Activators / chemistry
  • Enzyme Activators / pharmacology*
  • Female
  • Femoral Vein / drug effects
  • Femoral Vein / enzymology
  • Guanylate Cyclase / metabolism*
  • Heart / drug effects
  • Heart / physiology
  • Humans
  • Male
  • Morpholines / pharmacology*
  • Nitric Oxide* / physiology
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacology
  • Pyridines / chemistry
  • Pyridines / pharmacology
  • Pyrimidines / pharmacology*
  • Rabbits
  • Rats
  • Rats, Wistar
  • Swine
  • Vasodilation / drug effects
  • Vasodilation / physiology

Substances

  • 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
  • BAY 41-8543
  • Enzyme Activators
  • Morpholines
  • Pyrazoles
  • Pyridines
  • Pyrimidines
  • Nitric Oxide
  • Guanylate Cyclase